Patients and Methods
The study was approved by the the Ethics Committee of Renmin Hospital of Wuhan University (No. WDRY2020-K019). The requirement for written informed consent was waived in consideration of emerging infectious diseases.The study included data from 239 COVID-19 patients in Renmin Hospital of Wuhan University in China from December 31, 2020 to April 20, 2020. Patients diagnostic criteria about COVID-19: Real-time fluorescent RT-PCR was used to detect COVID-19 in nasal or pharyngeal swab specimens, and patients with positive results twice were included in the study. In addition, relevant clinical symptoms, laboratory parameters, and major treatments were also included. The outcomes of the patients included improvement to discharge criteria or worsening to death. The patient discharge criteria and clinical types shall be based on the COVID-19 diagnosis and treatment protocol version 6.
Clinical characteristics andtherapeutic modalities
The following clinical symptoms were recruited in the study: 1. The upper respiratory tract symptoms such as cough, runny nose or sneezing, 2. Oppression in chest or dyspnea , 3. Muscle pain, 4. Headache, 5. Gastrointestinal symptoms such as nausea, vomiting and diarrhea, 6. Comorbidities, 7. Body temperature, 8. Time from onset to admission, 9. Total time in hospital, Comorbidities included a history of pulmonary basic disease (chronic obstructive pulmonary disease, lung cancer,  bacterial pneumonia, pulmonary heart disease, et.al),hypertension,coronary artery disease, diabetes,cerebral infarction. Clinical characters include clinical symptoms, time from symptom onset to hospitalization, total length of hospitalization, treatment and medication, and disease outcome.